About Rivus Pharmaceuticals
Rivus Pharmaceuticals is a private company based in Charlottesville, Virginia. It has reported $223,479,132 raised in four offerings on Form D since October 2021.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jan 7, 2025 | Jan 16, 2025 | $56,979,133fully sold | 7 | $8.1M | EquityRule 506(b) | Form D ↗ |
| Aug 9, 2024 | Sep 17, 2024 | $66,000,000fully sold | 7 | $9.4M | EquityRule 506(b) | Form D ↗ |
| Aug 19, 2022 | Sep 17, 2024 | $65,999,999fully sold | 7 | $9.4M | EquityRule 506(b) | Form D ↗ |
| Mar 26, 2019 | Oct 4, 2021 | $34,500,000of $35.0M target | 4 | $8.6M | Equity, Options, Securities on exercise, Conversion of other rights to acquire shares of stock and the offer and sale of shares of preferred stock and the underlying shares of common stock issuable upon conversion thereof.Rule 506(b) | Form D ↗ |
| Total, four offerings | $223,479,132 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Rivus Pharmaceuticals's Form D filed Jan 16, 2025.
RS
Robert Schott
Executive officer
SK
Shaharyar Khan
Executive officer and director
RW
Rick Winningham
Director
AC
Allen Cunningham
Chief Operating Officer and director
JD
Jayson Dallas
Executive officer and director
TN
Tom O'Neil
Executive officer
DD
Derek DiRocco
Director
IS
Ian Smith
Director
EL
Erin Lavelle
Director
FR
Francesco De Rubertis
Director
Earlier filings also listed Nancy Hargreaves (executive officer, last listed Sep 2024) and Patrick Enright (director, last listed Oct 2021).